Search

The utilization of biochar's as soil amendments for enhancing nutrient retention in subsoils present potential limitations. To address this issue, we conducted a greenhouse experiment to assess the effects of various biochar's derived from animal manures (swine manure, poultry litter, cattle manure) and plant residues (rice straw, soybean straw, corn straw) when applied to surface of an acidic soil. Our study focused on wheat crops under a no-tillage system, with a subsequent evaluation of the residual impacts on soybeans. The experimental design involved the application of biochar's at different rates i.e. 10 and 20 Mg ha -1 , followed by the assessment of their influence on NPK levels, pH, and exchangeable Al in stratified soil layers (0-5, 5-10, 10-15, and 15-25 cm). Furthermore, we investigated the interplay between biochar doses and the application of nitrogen (N) in the top 5 cm of soil, specifically examining NO 3 - , NH 4 + , P and K levels. Our findings revealed that in the top 5 cm of soil, biochar doses and N application significantly affected NO 3 - , NH 4 + , P and K concentrations. However, in deeper soil layers, no significant differences were observed among biochar doses with or without N application. Interestingly, K levels were impacted throughout all soil depths, regardless of the presence or absence of N application. Moreover, biochar application up to a 5 cm depth induced favorable changes in soil pH and reduced exchangeable Al. In contrast, deeper layers experienced a decrease in soil pH and an increase in exchangeable Al following biochar treatment. In conclusion, our study demonstrates that biochar's can effectively retain NPK nutrients, enhance soil pH, and decrease exchangeable Al, independent of the type and dosage of application under a no-tillage system. Nonetheless, the efficacy of biochar amendments may vary with soil depth and type of nutrient, warranting careful consideration for maximizing their benefits in sustainable agricultural practices., (© 2024. The Author(s).)

Background: According to the American Physical Therapy Association, there is strong evidence to show that vertebral mobilization and manipulation procedures can be used to improve spinal and hip mobility and reduce pain and incapacity in low back pain patients that fit the clinical prediction rule., Objectives: To evaluate the immediate effects of high-velocity low-amplitude (HVLA) manipulation on pain and postural control parameters in individuals with nonspecific low back pain., Methods: This study used a participant-blinded and assessor-blinded randomized controlled clinical trial involving a single session, in which 24 participants were randomly distributed into control (simulated manipulation) and intervention (HVLA lumbar manipulation) groups. The primary (pain: subjective pain intensity and pressure pain threshold) and secondary outcomes (postural control: ellipse area, center of pressure [COP] excursion, COP RMS velocity, and differences between the COP and center of projected gravity) were evaluated before and after the session using a numerical pain scale, algometer, and a force platform. For all outcomes, multiple mixed 2 (group) × 2 (time) ANOVAs were performed., Results: For the subjective pain intensity, only time was significant as a main effect, where pre-intervention presented a greater value then post-intervention (F [1.44] = 4.377; p = 0.042; r = 0.30). For the pressure pain threshold no significant effect was found. For the postural control parameters, as a main effect, only the ellipse area was significantly greater in the control group (F [1.44] = 6.760; p = 0.013; effect size = 0.36)., Conclusions: There was a reduction in subjective pain intensity, evaluated using a numerical scale, in both the intervention and control groups immediately after the intervention, suggesting that the spinal manipulation had a similar effect to the placebo procedure. No effect of HVLA lumbar manipulation was identified for postural control variables in either the intervention or control groups., Trial Registration: The study was registered at ClinicalTrials.gov under the number NCT02312778, registered at 14 September 2014.